An integrated approach for identification and target validation of antifungal compounds active against Erg11p

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4233-4240

  Hoepfner, Dominic ^a   Karkare, Shantanu ^a   Helliwell, Stephen B ^a   Pfeifer, Martin ^a   Trunzer, Markus ^a   De Bonnechose, Sophie ^a   Zimmerlin, Alfred ^a   Tao, Jianshi ^b   Richie, Daryl ^b   Hofmann, Andreas ^a   Reinker, Stefan ^a   Frederiksen, Mathias ^a   Movva, N Rao ^a   Porter, Jeffrey A ^b   Ryder, Neil S ^b   Parker, Christian N ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYTOCHROME P450; HEME; PROTEIN ERG11P; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOCHEMISTRY; CANDIDA; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ERG11 GENE; FUNGAL GENE; FUNGAL STRAIN; GENETICS; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; HIGH-THROUGHPUT SCREENING ASSAYS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PROTEIN STRUCTURE, QUATERNARY; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

EID: 84864389651     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06332-11     Document Type: Article

References (39)

1. Aoyama Y, Okikawa T, Yoshida Y. 1981. Evidence for the presence of cytochrome P-450 functional in lanosterol 14 alpha-demethylation in microsomes of aerobically grown respiring yeast. Biochim. Biophys. Acta 665:596-601.
2. Barbosa MDFS, Yang G, Fang J, Kurilla MG, Pompliano DL. 2002. Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors. Antimicrob. Agents Chemother. 46:943-946. (Pubitemid 34260334)
3. Bard M, et al. 1993. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28:963-967. (Pubitemid 23333690)
4. Benkert P, Künzli M, Schwede T. 2009. QMEAN server for protein model quality estimation. Nucleic Acids Res. 37:W510-W514.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-2A. CLSI, Wayne, PA.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. CLSI, Wayne PA.
7. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195-204.
8. Fostel JM, Lartey PA. 2000. Emerging novel antifungal agents. Drug Discov. Today 5:25-32. (Pubitemid 30069656)
9. Fraczek MG, Bromley M, Bowyer P. 2011. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob. Agents Chemother. 55:2483-2486.
10. Ghannoum MA, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517. (Pubitemid 29484744)
11. Giaever G, et al. 2004. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. U. S. A. 101:793-798. (Pubitemid 38121037)
12. Hawksworth DL. 2001. The magnitude of fungal diversity: the 1.5 million species estimate revisited. Mycol. Res. 105:1422-1432. (Pubitemid 34134581)
13. Hillenmeyer ME, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320:362-365. (Pubitemid 351555656)
14. Ho CH, et al. 2009. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat. Biotechnol. 27:369-377.
15. Holm L, Park J. 2000. DaliLite workbench for protein structure comparison. Bioinformatics 16:566 -567.
16. Hoon S, St Onge RP, Giaever G, Nislow C. 2008. Yeast chemical genomics and drug discovery: an update. Trends Pharmacol. Sci. 29:499 -504.
17. Huang Y, Maraia RJ. 2001. Comparison of the RNA polymerase III transcription machinery in Schizosaccharomyces pombe, Saccharomyces cerevisiae and human. Nucleic Acids Res. 29:2675-2690. (Pubitemid 32685030)
18. Jacobson MP, et al. 2004. A hierarchical approach to all-atom protein loop prediction. Proteins 55:351-367. (Pubitemid 38437493)
19. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:630-637. (Pubitemid 36259570)
20. Kontoyiannis DP, Sagar N, Hirschi KD. 1999. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 43:2798 -2800.
21. Lees N, Skaggs B, Kirsch D, Bard M. 1995. Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review. Lipids 30:221-226.
22. Lees NDD. 1999. Biochemistry and molecular biology of sterol synthesis in Saccharomyces cerevisiae. Crit. Rev. Biochem. Mol. Biol. 34:33- 47.
23. Mallory JC, et al. 2005. Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae. Mol. Cell Biol. 25:1669 -1679.
24. Manavathu EK, Cutright JL, Chandrasekar PH. 1998. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 42:3018 -3021.
25. O'Brien J, Wilson I, Orton T, Pognan F. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267:5421-5426.
26. Parks L, Smith S, Crowley J. 1995. Biochemical and physiological effects of sterol alterations in yeast - a review. Lipids 30:227-230.
27. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. (Pubitemid 46020284)
28. Pearson MM, Rogers PD, Cleary JD, Chapman SW. 2003. Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 37:420-432. (Pubitemid 36249646)
29. Pierce SE, Davis RW, Nislow C, Giaever G. 2007. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat. Protoc. 2:2958 -2974.
30. Radford SA, Johnson EM, Warnock DW. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841- 843.
31. Smith C. 2003. Drug target validation: hitting the target. Nature 422:341-347.
32. Söding J, Biegert A, Lupas AN. 2005. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 33:W244-W248. (Pubitemid 44529917)
33. Strushkevich N, Usanov SA, Park H-W. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. J. Mol. Biol. 397:1067-1078.
34. Thevissen K, et al. 2007. Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. J. Biol. Chem. 282:21592-21597. (Pubitemid 47195737)
35. Venkateswarlu K, Kelly DE, Manning NJ, Kelly SL. 1998. NADPH cytochrome P-450 oxidoreductase and susceptibility to ketoconazole. Antimicrob. Agents Chemother. 42:1756 -1761.
36. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. 2003. Improved protein-ligand docking using GOLD. Proteins 52:609-623. (Pubitemid 37034158)
37. Wisplinghoff H, et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309 -317.
38. Xu D, et al. 2007. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog. 3:e92. doi:10.1371/journal.ppat.0030092.
39. Zhang J-H, Chung TDY, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. (Pubitemid 29278954)